Form 4: Matthew Strobeck Acquires Convertible Preferred Stock in Bio-Rad Laboratories

Matthew Strobeck, a director of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock that can be converted into common stock pending stockholder approval.

Summary

• Matthew Strobeck, a director of Biodesix Inc., filed a Form 4 indicating changes in beneficial ownership.
• On April 5, 2024, Strobeck acquired 1,304 shares of Series A Non-Voting Convertible Preferred Stock, indirectly held through Birchview Capital Separately Managed Account, convertible into 52,160 shares of common stock at $46.
• Additionally, Strobeck acquired 7,392 shares of Series A Non-Voting Convertible Preferred Stock, indirectly held through Birchview Fund LLC, convertible into 295,680 shares of common stock at $46.
• The conversion of the preferred stock into common stock is subject to stockholder approval at the 2024 annual meeting.
• Strobeck is prohibited from converting shares if it results in him and his affiliates beneficially owning more than 19.9% of the outstanding common stock.
• Strobeck has sole voting and dispositive power over the shares held by Birchview Fund, LLC and Birchview Capital Separately Managed Account but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Form 4) detailing a transaction by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Risks

• The conversion of preferred stock to common stock is contingent on stockholder approval, which is not guaranteed.
• The conversion is subject to limitations that prevent Strobeck from exceeding 19.9% ownership, potentially limiting the full benefit of the conversion.

Future Outlook

The conversion of the preferred stock is contingent upon stockholder approval at the 2024 annual meeting.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and principal stockholders) to report transactions in their company's stock, providing transparency to the market.

Stakeholder Impact

• Shareholders: Potential dilution of common stock if the preferred stock is converted.
• Company: Potential increase in outstanding common stock upon conversion, affecting earnings per share.

Next Steps

• Stockholder vote on the conversion proposal at the 2024 annual meeting.
• Potential conversion of preferred stock to common stock, subject to limitations.

Key Dates